Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Paola Vallejo Armenta"'
Autor:
Diana Trujillo-Benítez, Myrna Luna-Gutiérrez, José G. Aguirre-De Paz, Pedro Cruz-Nova, Gerardo Bravo-Villegas, Joel E. Vargas-Ahumada, Paola Vallejo-Armenta, Enrique Morales-Avila, Nallely Jiménez-Mancilla, Rigoberto Oros-Pantoja, Clara Santos-Cuevas, Erika Azorín-Vega, Blanca Ocampo-García, Guillermina Ferro-Flores
Publikováno v:
Pharmaceutics, Vol 16, Iss 4, p 532 (2024)
Recently, we reported a new fibroblast activation protein (FAP) inhibitor radiopharmaceutical based on the 99mTc-((R)-1-((6-hydrazinylnicotinoyl)-D-alanyl) pyrrolidin-2-yl) boronic acid (99mTc-HYNIC-D-Alanine-BoroPro)(99mTc-HYNIC-iFAP) structure for
Externí odkaz:
https://doaj.org/article/0fdb43edc9aa47f6b9827a930acef9fb
Autor:
Paola Vallejo-Armenta, Guillermina Ferro-Flores, Clara Santos-Cuevas, Francisco Osvaldo García-Pérez, Pamela Casanova-Triviño, Bayron Sandoval-Bonilla, Blanca Ocampo-García, Erika Azorín-Vega, Myrna Luna-Gutiérrez
Publikováno v:
Pharmaceuticals, Vol 15, Iss 6, p 729 (2022)
Fibroblast activation protein (FAP) is highly expressed on the cancer-associated fibroblasts (CAF) of the tumor stroma. Recently, we reported the preclinical evaluation and clinical biokinetics of a novel 99mTc-labeled FAP inhibitor radioligand ([99m
Externí odkaz:
https://doaj.org/article/f2ad2f7d31e9443ab8f57f8657701df3
Autor:
Luis Coria-Domínguez, Paola Vallejo-Armenta, Myrna Luna-Gutiérrez, Blanca Ocampo-García, Brenda Gibbens-Bandala, Francisco García-Pérez, Gerardo Ramírez-Nava, Clara Santos-Cuevas, Guillermina Ferro-Flores
Publikováno v:
Pharmaceuticals, Vol 15, Iss 5, p 590 (2022)
Tumor microenvironment fibroblasts overexpress the fibroblast activation protein (FAP). We recently reported the preclinical evaluation of [99mTc]Tc-iFAP as a new SPECT radioligand capable of detecting FAP. This research aimed to evaluate the kinetic
Externí odkaz:
https://doaj.org/article/ea81d4c1c2ba436a9e74773c7fb4da5c
Autor:
Marylin Acuña Hernandez, Paola Vallejo Armenta, Uvi Cancino Ramos, Liset Sánchez Ordúz, Pamela Casanova Triviño, Leonardo Cadavid Blanco
Publikováno v:
Problems of Endocrine Pathology. 79:81-89
Thyroid cancer is a common endocrinological malignancy worldwide, accounting for 3% of the global incidence of all cancers. Meta-analyses, systematic reviews, and descriptive reviews mention the use of positron emission tomography / computed tomograp
Autor:
Marylin Acuña Hernández, Walter Efrén Roldán Cubides, David Cardoza Ochoa, Liset Sánchez Orduz, Paola Vallejo Armenta, Rodrigo Hernández Ramírez, Uvi Cancino Ramos
Publikováno v:
Neurología Argentina.
Autor:
Claudia G. Bautista-Wong, Bayron A. Sandoval-Bonilla, Jorge Iván González-Díaz, Rosa María Villanueva-Pérez, Bárbara Nettel-Rueda, Guillermina Ferro-Flores, Keren Contreras-Contreras, Clara Santos-Cuevas, Paola Vallejo-Armenta, Juan Soto-Andonaegui
Publikováno v:
Nuclear Medicine and Biology. :1-8
Background PSMA (prostate-specific membrane antigen) protein is heavily expressed in the proliferating microvasculature of high-grade gliomas (HGG) and brain metastases (BM). This research aimed to assess [99mTc]Tc-iPSMA SPECT brain imaging as a pote
Autor:
Paola Vallejo Armenta, Uvi Cancino Ramos, Marylin Acuña Hernández, Leonardo Cadavid Blanco, Liset Sanchez Orduz
Publikováno v:
Annals of nuclear medicine. 35(9)
Hyperparathyroidism is a common calcium metabolic disorder, characterized by the presence of high concentrations or inappropriately normal concentrations of parathyroid hormone (PTH) in the context of high calcium. Pharmacological and surgical manage
Autor:
Paola Vallejo-Armenta, Rosa María Villanueva-Pérez, Juan Soto-Andonaegui, Jorge Iván González-Díaz, Blanca Ocampo-García, Francisco O. García-Pérez, Guillermina Ferro-Flores, Myrna Luna-Gutiérrez, Clara Santos-Cuevas, Angélica Arrellano-Zarate, Erika Azorín-Vega
Publikováno v:
Contrast Media & Molecular Imaging, Vol 2020 (2020)
Contrast Media & Molecular Imaging
Contrast Media & Molecular Imaging
Overexpression of the chemokine-4 receptor (CXCR4) in brain tumors is associated with high cancer cell invasiveness. Recently, we reported the preclinical evaluation of 99mTc-CXCR4-L (cyclo-D-Tyr-D-[NMe]Orn[EDDA-99mTc-6-hydrazinylnicotinyl]-Arg-NaI-G